Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aptose Biosciences Inc (APS.TO)

Aptose Biosciences Inc (APS.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 123,587
  • Shares Outstanding, K 92,229
  • Annual Sales, $ 0 K
  • Annual Income, $ -65,354 K
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48
Trade APS.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.67
  • Most Recent Earnings -0.12 on 05/09/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.18
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.17 +15.38%
on 05/12/22
1.57 -14.01%
on 05/05/22
-0.11 (-7.53%)
since 04/20/22
3-Month
1.17 +15.38%
on 05/12/22
1.92 -29.69%
on 04/04/22
-0.13 (-8.78%)
since 02/18/22
52-Week
1.17 +15.38%
on 05/12/22
6.98 -80.66%
on 06/08/21
-5.09 (-79.04%)
since 05/20/21

Most Recent Stories

More News
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Aptose Reports Results for the First Quarter 2022

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Stocks in play: Aptose Biosciences Inc.

Today announced that CEO William G. Rice will participate in the RBC Capital Markets Global Healthcare ...

APS.TO : 1.37 (+2.24%)
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Stocks in play: Aptose Biosciences Inc.

Will report financial results for the quarter ended March 31, on Monday, May 9, after the close of the ...

APS.TO : 1.37 (+2.24%)
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Aptose Announces Executive Management Changes

─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07,...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 1.0700 (+1.90%)
APS.TO : 1.37 (+2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 1.40
2nd Resistance Point 1.39
1st Resistance Point 1.36
Last Price 1.37
1st Support Level 1.32
2nd Support Level 1.31
3rd Support Level 1.28

See More

52-Week High 6.98
Fibonacci 61.8% 4.76
Fibonacci 50% 4.07
Fibonacci 38.2% 3.39
Last Price 1.37
52-Week Low 1.17

See More

Business Summary

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib,...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar